These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Aminoterminal B-type natriuretic peptide (NT-proBNP) in end-stage renal failure patients on regular hemodialysis: does it have diagnostic and prognostic implications? Pimenta J; Sampaio F; Martins P; Carvalho B; Rocha-Gonçalves F; Ferreira A; Bettencourt P Nephron Clin Pract; 2009; 111(3):c182-8. PubMed ID: 19194108 [TBL] [Abstract][Full Text] [Related]
25. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860 [TBL] [Abstract][Full Text] [Related]
26. [Troponins and chronic renal failure in dialysis patients]. Bertinchant JP Arch Mal Coeur Vaiss; 2004 Feb; 97(2):157-64. PubMed ID: 15032416 [TBL] [Abstract][Full Text] [Related]
27. [Cardiovascular risk markers in hemodialysis]. Urso S; Milone F; Garozzo M; Cannavò ME; Biondi A; Battaglia G G Ital Nefrol; 2004; 21 Suppl 30():S212-6. PubMed ID: 15750988 [TBL] [Abstract][Full Text] [Related]
28. Assessing cardiovascular disease in the dialysis patient. Baig SZ; Coats WC; Aggarwal KB; Alpert MA Adv Perit Dial; 2009; 25():147-54. PubMed ID: 19886337 [TBL] [Abstract][Full Text] [Related]
29. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ; J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular biomarkers in the ICU. Noveanu M; Mebazaa A; Mueller C Curr Opin Crit Care; 2009 Oct; 15(5):377-83. PubMed ID: 19606027 [TBL] [Abstract][Full Text] [Related]
31. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis. Al-Hweish A; Sultan SS; Mogazi K; Elsammak MY Hemodial Int; 2010 Jul; 14(3):308-15. PubMed ID: 20597992 [TBL] [Abstract][Full Text] [Related]
32. [Redefinition of myocardial infarction--relevance of biomarkers]. Weber M; Hamm C Herz; 2008 Mar; 33(2):115-21. PubMed ID: 18344030 [TBL] [Abstract][Full Text] [Related]
34. Biomarkers of cardiovascular damage. Collinson PO; Gaze DC Med Princ Pract; 2007; 16(4):247-61. PubMed ID: 17541289 [TBL] [Abstract][Full Text] [Related]
35. N-terminal pro B-type natriuretic peptide identifies patients with chest pain at high long-term cardiovascular risk. van der Zee PM; Cornel JH; Bholasingh R; Fischer JC; van Straalen JP; De Winter RJ Am J Med; 2011 Oct; 124(10):961-9. PubMed ID: 21962317 [TBL] [Abstract][Full Text] [Related]
36. Cardiac troponins in renal failure - time for an optimistic consensus? Buhaescu I; Izzedine H; Covic A Int J Clin Pract; 2005 Nov; 59(11):1317-25. PubMed ID: 16236087 [TBL] [Abstract][Full Text] [Related]
37. Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction. Odar-Cederlöf I; Bjellerup P; Williams A; Blagg CR; Twardowski Z; Ting G; Kjellstrand CM Hemodial Int; 2006 Oct; 10(4):394-8. PubMed ID: 17014518 [TBL] [Abstract][Full Text] [Related]